Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 10 | 2007 | 796 | 1.480 |
Why?
|
| Spironolactone | 4 | 2012 | 39 | 1.390 |
Why?
|
| Aldosterone | 7 | 2012 | 66 | 1.270 |
Why?
|
| Oxidative Stress | 8 | 2006 | 938 | 1.020 |
Why?
|
| Blood Pressure | 14 | 2012 | 646 | 0.960 |
Why?
|
| Nitric Oxide | 11 | 2011 | 316 | 0.880 |
Why?
|
| Kidney | 6 | 2012 | 337 | 0.870 |
Why?
|
| Glutathione | 9 | 2007 | 179 | 0.810 |
Why?
|
| Sodium Chloride, Dietary | 5 | 2011 | 41 | 0.800 |
Why?
|
| Losartan | 3 | 2007 | 32 | 0.790 |
Why?
|
| Endothelium, Vascular | 4 | 2007 | 237 | 0.710 |
Why?
|
| Angiotensin II | 6 | 2007 | 97 | 0.690 |
Why?
|
| Epoprostenol | 8 | 2012 | 25 | 0.680 |
Why?
|
| Rats, Inbred Dahl | 9 | 2012 | 33 | 0.620 |
Why?
|
| Rats | 18 | 2012 | 3483 | 0.590 |
Why?
|
| Dinoprost | 3 | 2011 | 22 | 0.570 |
Why?
|
| Simvastatin | 2 | 2007 | 29 | 0.560 |
Why?
|
| Thromboxane A2 | 6 | 2007 | 20 | 0.520 |
Why?
|
| Plant Oils | 2 | 2005 | 18 | 0.470 |
Why?
|
| Superoxides | 4 | 2007 | 53 | 0.430 |
Why?
|
| Cyclooxygenase 1 | 1 | 2012 | 11 | 0.420 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 104 | 0.400 |
Why?
|
| Heart Rate | 6 | 2012 | 253 | 0.380 |
Why?
|
| Antihypertensive Agents | 2 | 2004 | 284 | 0.380 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 161 | 0.340 |
Why?
|
| Animals | 19 | 2012 | 15081 | 0.320 |
Why?
|
| Membrane Proteins | 1 | 2012 | 517 | 0.320 |
Why?
|
| Sodium, Dietary | 2 | 2007 | 27 | 0.310 |
Why?
|
| Sulfates | 1 | 2007 | 23 | 0.290 |
Why?
|
| Sulfhydryl Compounds | 1 | 2007 | 47 | 0.290 |
Why?
|
| Metals | 1 | 2007 | 98 | 0.280 |
Why?
|
| Enalapril | 1 | 2006 | 7 | 0.270 |
Why?
|
| Cyclic N-Oxides | 1 | 2006 | 18 | 0.270 |
Why?
|
| Soil Pollutants | 1 | 2007 | 87 | 0.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 69 | 0.270 |
Why?
|
| Soil | 1 | 2007 | 130 | 0.270 |
Why?
|
| Male | 15 | 2012 | 20025 | 0.250 |
Why?
|
| Amlodipine | 1 | 2004 | 21 | 0.250 |
Why?
|
| Body Weight | 4 | 2011 | 434 | 0.240 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2005 | 1618 | 0.210 |
Why?
|
| Antioxidants | 1 | 2006 | 416 | 0.210 |
Why?
|
| Angiotensin I | 1 | 2002 | 5 | 0.210 |
Why?
|
| Salts | 1 | 2002 | 16 | 0.210 |
Why?
|
| Acetophenones | 2 | 2012 | 10 | 0.200 |
Why?
|
| Systole | 2 | 2012 | 61 | 0.200 |
Why?
|
| Diet | 1 | 2007 | 801 | 0.190 |
Why?
|
| Isoprostanes | 3 | 2005 | 14 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2002 | 308 | 0.170 |
Why?
|
| Aorta | 3 | 2005 | 167 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2012 | 859 | 0.170 |
Why?
|
| Cyclic GMP | 3 | 2004 | 47 | 0.170 |
Why?
|
| Buthionine Sulfoximine | 3 | 2003 | 12 | 0.170 |
Why?
|
| Disease Models, Animal | 4 | 2006 | 1371 | 0.160 |
Why?
|
| Dinoprostone | 2 | 2012 | 63 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2006 | 1369 | 0.140 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2007 | 37 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2007 | 77 | 0.130 |
Why?
|
| Mesenteric Arteries | 2 | 2005 | 20 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 227 | 0.130 |
Why?
|
| Organ Size | 2 | 2005 | 157 | 0.130 |
Why?
|
| Rats, Inbred SHR | 2 | 2007 | 32 | 0.130 |
Why?
|
| Sodium Chloride | 2 | 2006 | 55 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 108 | 0.120 |
Why?
|
| Thromboxane B2 | 2 | 2004 | 9 | 0.110 |
Why?
|
| Myocardium | 2 | 2005 | 235 | 0.110 |
Why?
|
| Cyclic AMP | 2 | 2004 | 131 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2012 | 41 | 0.100 |
Why?
|
| Urinalysis | 1 | 2011 | 30 | 0.100 |
Why?
|
| Proteinuria | 1 | 2011 | 50 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1039 | 0.090 |
Why?
|
| Sodium | 1 | 2011 | 103 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2011 | 87 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 433 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 893 | 0.090 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2007 | 11 | 0.080 |
Why?
|
| Phytochelatins | 1 | 2007 | 3 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2007 | 119 | 0.070 |
Why?
|
| Plant Leaves | 1 | 2007 | 124 | 0.070 |
Why?
|
| Spin Labels | 1 | 2006 | 9 | 0.070 |
Why?
|
| Prostaglandins | 1 | 2005 | 27 | 0.070 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 56 | 0.070 |
Why?
|
| Vasoconstriction | 1 | 2005 | 42 | 0.070 |
Why?
|
| Lipids | 1 | 2007 | 235 | 0.070 |
Why?
|
| Acetylcholine | 1 | 2005 | 73 | 0.070 |
Why?
|
| Glutathione Disulfide | 1 | 2005 | 8 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2006 | 177 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 37 | 0.060 |
Why?
|
| Prostaglandins I | 1 | 2005 | 1 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2005 | 36 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2005 | 34 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1015 | 0.060 |
Why?
|
| Second Messenger Systems | 1 | 2004 | 14 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 139 | 0.060 |
Why?
|
| 4-Aminopyridine | 1 | 2003 | 7 | 0.060 |
Why?
|
| Pupil | 1 | 2003 | 8 | 0.060 |
Why?
|
| Potassium Channel Blockers | 1 | 2003 | 33 | 0.060 |
Why?
|
| Aqueous Humor | 1 | 2003 | 18 | 0.060 |
Why?
|
| Heart | 1 | 2005 | 180 | 0.060 |
Why?
|
| F2-Isoprostanes | 1 | 2003 | 20 | 0.060 |
Why?
|
| Clenbuterol | 1 | 2003 | 12 | 0.060 |
Why?
|
| Hindlimb Suspension | 1 | 2003 | 14 | 0.060 |
Why?
|
| Intraocular Pressure | 1 | 2003 | 112 | 0.060 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2003 | 28 | 0.050 |
Why?
|
| Spermidine | 1 | 2003 | 33 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 49 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2003 | 51 | 0.050 |
Why?
|
| Computer Graphics | 1 | 2002 | 17 | 0.050 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2002 | 4 | 0.050 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2002 | 4 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 62 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 282 | 0.050 |
Why?
|
| Vitamin D | 1 | 2003 | 196 | 0.050 |
Why?
|
| Time Factors | 1 | 2002 | 1742 | 0.040 |
Why?
|
| Norepinephrine | 2 | 2003 | 110 | 0.030 |
Why?
|
| Ocular Hypertension | 1 | 2003 | 17 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 283 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 33 | 0.010 |
Why?
|
| Epinephrine | 1 | 2003 | 36 | 0.010 |
Why?
|
| Nonlinear Dynamics | 1 | 2003 | 33 | 0.010 |
Why?
|
| Reducing Agents | 1 | 2002 | 13 | 0.010 |
Why?
|
| Reference Standards | 1 | 2002 | 52 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 58 | 0.010 |
Why?
|
| Solutions | 1 | 2002 | 62 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 181 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 421 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 677 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 935 | 0.010 |
Why?
|
| Female | 2 | 2003 | 20969 | 0.010 |
Why?
|
| Humans | 1 | 2002 | 37093 | 0.000 |
Why?
|